For example, a fraction of non-small cell lung carcinoma (NSCLC), inflammatory myofibroblastic tumor, and anaplastic large cell lymphoma, which share ALK fusions, can be treated with ALK inhibitors and this strategy has shown clinical efficacy [16]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.